Download PDFPDF
Heparin-induced thrombocytopaenia
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    role of new oral anticoagulants in mitigating the risk of heparin-induced thrombocytopenia in cancer patients

    Given the fact that the risk of heparin-induced thrombocytopenia (HIT) is higher with prolonged therapy, the new oral anticoagulants (NOACs) might have a role in shortening the duration of low molecular weight heparin (LMWH) thromboprophylaxis in cancer patients from its currently recommended minimum of 3 months (1) to a much shorter duration by facilitating a transition to NOACSs( 2). That strategy might mitigate the risk of occurrence of HIT.
    Currently, international guidelines recommend LMWH instead of warfarin for management of cancer-related venous thromboembolism (1), but the duration of that management strategy puts patients at risk of HIT, with all its attendant consequences. In an open-label, noninferiority trial, patients with cancer-associated venous thromboembolism were randomly assigned to LMWH for at least 5 days followed by oral edoxaban (60 mg/day) (edoxaban group) or subcutaneous dalteparin at an appropriate dose. Treatment duration in both cases was at least 6 months. In that study, recurrent venous thromboembolism occurred in 7.9% of the edoxaban group vs. 11.3% of the dalteparin group (P=0.09). Major bleeding occurred in 6.9% of the edoxaban group vs. 4% of the dalteparin group (P=0.04). The increase in major bleeding was principally attributable to upper gastrointestinal bleeding in patients who had gastric cancer (2). A criticism of that study is that the 60 mg/day of edoxaban is inherently associated with significantly (P=0.03) greater risk of...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    The emerging role of new oral anticoagulants in HIT

    In their excellent review the authors drew attention to alternative oral anticoagulants to manage heparin-induced thrombocytopenia(HIT)(1). The American College of Chest Physicians guideline for HIT and HIT-associated thrombosis(HITT) cautions against premature transition to vitamin K antagonist therapy due to significant risk of warfarin-induced skin necrosis or development of venous limb gangrene(2). According to a recent review, the new oral anticoagulants(NOACs) are not burdened with that disadvantage, and their rapid onset of action generates a smooth transition to forward anticoagulation in patients with HIT/HITT. Furthermore, NOACs do not cross-react with HIT antibodies(3). That review encompassed data from 56 HIT/HITT patients subsequently treated with NOACs. Data were derived from 3 studies and 8 case reports. Mean age of the 56 patients was 70, twenty four had HIT, and thirty two had HITT. At the time of HIT/HITT diagnosis a nonheparin parenteral agent was initiated in 42, and the remaining 14 transitioned to NOACs straightaway. The NOACS used in the 56 patients were rivaroxaban, apixaban, and dabigatran in 54%, 29%, and 18% of cases, respectively. There were only 2 instances of recurrent thrombosis with NOAC therapy. Major bleeding occurred in 3 patients who did not appear to be on NOAC therapy at the time of the bleed.
    (1) Prince M., Wenham T
    Heparin-induced thrombocytopemia
    Postgrad Med J 2018;94:453-547
    (2)Linkins L-A....

    Show More
    Conflict of Interest:
    None declared.